BIO-CHEM(SH:603360)2021-10-28 16:00Financial Performance - The company's operating revenue for Q3 2021 was CNY 216,757,283.85, representing a year-on-year increase of 28.14%[5] - The net profit attributable to shareholders for Q3 2021 was CNY 37,016,596.19, a decrease of 27.20% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,060,722.47, down 27.78% year-on-year[5] - The basic earnings per share for Q3 2021 was CNY 0.14, a decrease of 26.32% compared to the previous year[6] - The company achieved a revenue of CNY 691,950,199.90 for the year-to-date period, with a growth of 22.07% compared to the previous year[5] - Net profit for the first three quarters of 2021 was ¥160,132,910.73, compared to ¥178,809,189.22 in the same period of 2020, reflecting a decrease of approximately 10.5%[19] - The net profit attributable to the parent company for Q3 2021 was ¥160,132,910.73, a decrease of 10.5% compared to ¥178,809,189.22 in Q3 2020[20] - The total comprehensive income for Q3 2021 was ¥160,129,604.32, down from ¥178,818,813.85 in Q3 2020, indicating a decline of 10.5%[20] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was CNY 110,730,001.27, showing a decline of 37.70%[6] - Cash flow from operating activities for the first nine months of 2021 was ¥110,730,001.27, a decrease of 37.7% compared to ¥177,745,793.52 in the same period of 2020[24] - The company's cash and cash equivalents decreased to ¥259,973,709.50 from ¥333,068,462.74, a decline of about 22.0%[15] - The cash and cash equivalents at the end of Q3 2021 were ¥171,751,306.49, a decrease from ¥340,900,855.18 at the end of Q3 2020[25] - The company's total assets as of September 30, 2021, amounted to ¥1,575,314,359.12, an increase from ¥1,429,695,956.74 at the end of 2020, showing a growth of about 10.2%[16] Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥504,962,989.47, up from ¥365,746,716.33 in 2020, indicating an increase of about 38.1%[18] - The company reported a financial expense of ¥4,875,748.81 for the first three quarters of 2021, compared to ¥3,276,229.29 in 2020, representing an increase of about 48.8%[19] - Research and development expenses for the first three quarters of 2021 were ¥24,939,361.32, up from ¥19,438,181.25 in 2020, indicating an increase of approximately 28.6%[19] Equity and Liabilities - Current liabilities totaled ¥571,927,752.96 as of September 30, 2021, compared to ¥396,049,476.04 at the end of 2020, representing an increase of approximately 44.2%[16] - The total equity attributable to shareholders decreased to ¥961,270,047.38 from ¥988,283,192.35, a decline of approximately 2.7%[16] Business Strategy - The company plans to adjust product prices in response to fluctuations in raw material costs to alleviate cost pressures[12] - The industrial biocide business continues to show stable growth, although profit growth has slowed due to rising raw material prices[12] Cash Flow from Activities - Total cash inflow from investing activities was ¥10,365,250.00, while cash outflow was ¥173,777,347.45, resulting in a net cash outflow of ¥163,412,097.45 for the first nine months of 2021[25] - Cash inflow from financing activities for the first nine months of 2021 was ¥640,271,307.00, significantly higher than ¥330,000,000.00 in the same period last year, marking an increase of 94.5%[25] - The net cash flow from financing activities was ¥45,211,675.42, compared to a minimal increase of ¥353,425.32 in the same period of 2020[25] Other Comprehensive Income - The company received ¥23,159,625.54 in tax refunds related to operating activities, an increase from ¥10,184,577.94 in the same period last year[24] - The company reported a decrease in other comprehensive income after tax, with a net amount of -¥3,306.41 for Q3 2021 compared to ¥9,624.63 in Q3 2020[20]